| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiac Resynchronization Therapy | 38 | 2023 | 66 | 13.020 |
Why?
|
| Bundle of His | 19 | 2023 | 41 | 8.320 |
Why?
|
| Bundle-Branch Block | 21 | 2023 | 47 | 7.580 |
Why?
|
| Atrial Fibrillation | 16 | 2023 | 269 | 5.250 |
Why?
|
| Heart Failure | 28 | 2023 | 1161 | 5.210 |
Why?
|
| Electrocardiography | 29 | 2023 | 473 | 5.010 |
Why?
|
| Defibrillators, Implantable | 16 | 2023 | 129 | 4.920 |
Why?
|
| Tachycardia, Ventricular | 16 | 2023 | 115 | 3.610 |
Why?
|
| Catheter Ablation | 19 | 2023 | 226 | 2.920 |
Why?
|
| Cardiac Pacing, Artificial | 14 | 2022 | 87 | 2.300 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 9 | 2020 | 39 | 2.060 |
Why?
|
| Heart Conduction System | 13 | 2023 | 106 | 1.970 |
Why?
|
| Arrhythmias, Cardiac | 12 | 2023 | 186 | 1.870 |
Why?
|
| Heart Rate | 10 | 2023 | 486 | 1.790 |
Why?
|
| Heart Ventricles | 14 | 2020 | 752 | 1.630 |
Why?
|
| Cardiac Resynchronization Therapy Devices | 7 | 2019 | 19 | 1.370 |
Why?
|
| Treatment Outcome | 38 | 2023 | 7829 | 1.320 |
Why?
|
| Pacemaker, Artificial | 6 | 2021 | 86 | 1.230 |
Why?
|
| Humans | 95 | 2023 | 84493 | 1.100 |
Why?
|
| Anti-Arrhythmia Agents | 3 | 2019 | 57 | 1.040 |
Why?
|
| Tachycardia, Atrioventricular Nodal Reentry | 3 | 2020 | 20 | 0.950 |
Why?
|
| Cardiomyopathies | 7 | 2020 | 237 | 0.940 |
Why?
|
| Body Surface Potential Mapping | 5 | 2021 | 22 | 0.920 |
Why?
|
| Heart Septum | 2 | 2020 | 45 | 0.910 |
Why?
|
| Echocardiography | 9 | 2019 | 895 | 0.900 |
Why?
|
| Mitral Valve Insufficiency | 4 | 2019 | 185 | 0.890 |
Why?
|
| Aged | 44 | 2023 | 18159 | 0.810 |
Why?
|
| Heart Atria | 3 | 2020 | 238 | 0.780 |
Why?
|
| Anticoagulants | 2 | 2023 | 400 | 0.750 |
Why?
|
| Middle Aged | 36 | 2023 | 24751 | 0.730 |
Why?
|
| Purkinje Fibers | 1 | 2019 | 27 | 0.710 |
Why?
|
| Cardiac Imaging Techniques | 1 | 2019 | 25 | 0.710 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2019 | 73 | 0.690 |
Why?
|
| Female | 51 | 2023 | 43911 | 0.680 |
Why?
|
| Male | 50 | 2023 | 40460 | 0.660 |
Why?
|
| Atrioventricular Block | 3 | 2022 | 23 | 0.590 |
Why?
|
| Ventricular Function, Right | 1 | 2017 | 139 | 0.590 |
Why?
|
| Action Potentials | 2 | 2020 | 561 | 0.580 |
Why?
|
| Atrial Flutter | 4 | 2020 | 33 | 0.570 |
Why?
|
| Ventricular Function, Left | 7 | 2023 | 578 | 0.570 |
Why?
|
| Prospective Studies | 17 | 2023 | 4091 | 0.560 |
Why?
|
| Spinal Cord Stimulation | 1 | 2015 | 12 | 0.560 |
Why?
|
| Atrioventricular Node | 4 | 2020 | 33 | 0.560 |
Why?
|
| Surgical Procedures, Operative | 1 | 2018 | 182 | 0.560 |
Why?
|
| Hospitalization | 4 | 2018 | 817 | 0.530 |
Why?
|
| Cause of Death | 1 | 2015 | 273 | 0.510 |
Why?
|
| Death, Sudden, Cardiac | 2 | 2023 | 44 | 0.500 |
Why?
|
| Electric Countershock | 1 | 2012 | 47 | 0.450 |
Why?
|
| Streptococcal Infections | 1 | 2012 | 57 | 0.440 |
Why?
|
| Myocarditis | 1 | 2012 | 47 | 0.440 |
Why?
|
| Equipment Failure | 1 | 2012 | 118 | 0.430 |
Why?
|
| Postoperative Complications | 3 | 2021 | 2172 | 0.430 |
Why?
|
| Bradycardia | 2 | 2022 | 39 | 0.420 |
Why?
|
| Growth Differentiation Factor 10 | 1 | 2011 | 1 | 0.420 |
Why?
|
| Antigens, Ly | 1 | 2011 | 37 | 0.410 |
Why?
|
| Ventricular Fibrillation | 3 | 2023 | 65 | 0.410 |
Why?
|
| Incidence | 6 | 2018 | 1559 | 0.400 |
Why?
|
| Follow-Up Studies | 14 | 2021 | 3598 | 0.400 |
Why?
|
| Epicardial Mapping | 2 | 2021 | 10 | 0.390 |
Why?
|
| Ventricular Dysfunction, Left | 5 | 2014 | 306 | 0.390 |
Why?
|
| Sick Sinus Syndrome | 2 | 2021 | 9 | 0.390 |
Why?
|
| Ventricular Remodeling | 7 | 2020 | 94 | 0.380 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2011 | 126 | 0.380 |
Why?
|
| Monitoring, Physiologic | 1 | 2011 | 266 | 0.370 |
Why?
|
| Cicatrix | 3 | 2023 | 64 | 0.360 |
Why?
|
| Transforming Growth Factor beta | 1 | 2011 | 286 | 0.360 |
Why?
|
| Device Removal | 2 | 2021 | 159 | 0.350 |
Why?
|
| Mitral Valve | 3 | 2020 | 247 | 0.340 |
Why?
|
| Retrospective Studies | 19 | 2023 | 8152 | 0.330 |
Why?
|
| GTPase-Activating Proteins | 1 | 2008 | 65 | 0.320 |
Why?
|
| Wnt Proteins | 1 | 2008 | 123 | 0.320 |
Why?
|
| Prosthesis Implantation | 3 | 2021 | 123 | 0.320 |
Why?
|
| beta Catenin | 1 | 2008 | 246 | 0.300 |
Why?
|
| Digestive System Surgical Procedures | 2 | 2007 | 117 | 0.290 |
Why?
|
| Myocardial Ischemia | 4 | 2019 | 157 | 0.290 |
Why?
|
| Cohort Studies | 5 | 2019 | 2719 | 0.280 |
Why?
|
| Magnetic Resonance Imaging, Cine | 2 | 2020 | 155 | 0.280 |
Why?
|
| Predictive Value of Tests | 6 | 2021 | 1647 | 0.270 |
Why?
|
| Risk Factors | 9 | 2021 | 5313 | 0.260 |
Why?
|
| Myocardium | 2 | 2020 | 523 | 0.260 |
Why?
|
| Membrane Proteins | 1 | 2011 | 1181 | 0.250 |
Why?
|
| Lower Gastrointestinal Tract | 1 | 2004 | 8 | 0.250 |
Why?
|
| Aged, 80 and over | 9 | 2022 | 6457 | 0.250 |
Why?
|
| Patient Selection | 2 | 2022 | 684 | 0.250 |
Why?
|
| Electrodes, Implanted | 3 | 2012 | 166 | 0.240 |
Why?
|
| Heart-Assist Devices | 4 | 2018 | 716 | 0.220 |
Why?
|
| Feasibility Studies | 6 | 2021 | 742 | 0.220 |
Why?
|
| Ventricular Septum | 1 | 2022 | 11 | 0.220 |
Why?
|
| Stroke Volume | 3 | 2022 | 434 | 0.220 |
Why?
|
| Evidence-Based Medicine | 2 | 2016 | 425 | 0.220 |
Why?
|
| Ventricular Premature Complexes | 1 | 2021 | 6 | 0.210 |
Why?
|
| Prognosis | 5 | 2023 | 3626 | 0.210 |
Why?
|
| Treatment Failure | 3 | 2017 | 283 | 0.210 |
Why?
|
| Crohn Disease | 2 | 2007 | 714 | 0.210 |
Why?
|
| Pulmonary Veins | 2 | 2012 | 68 | 0.200 |
Why?
|
| Arrhythmogenic Right Ventricular Dysplasia | 1 | 2021 | 10 | 0.200 |
Why?
|
| Prosthesis-Related Infections | 1 | 2021 | 58 | 0.200 |
Why?
|
| Electrophysiology | 1 | 2021 | 399 | 0.200 |
Why?
|
| Global Health | 2 | 2021 | 192 | 0.190 |
Why?
|
| Severity of Illness Index | 4 | 2019 | 1756 | 0.190 |
Why?
|
| Gadolinium | 1 | 2020 | 102 | 0.190 |
Why?
|
| Infection Control | 1 | 2021 | 114 | 0.190 |
Why?
|
| Risk Assessment | 5 | 2020 | 2230 | 0.190 |
Why?
|
| Vena Cava, Superior | 1 | 2020 | 59 | 0.190 |
Why?
|
| Ultrasonography, Interventional | 1 | 2020 | 118 | 0.180 |
Why?
|
| Cardiac Catheters | 1 | 2019 | 9 | 0.180 |
Why?
|
| Cardiac Catheterization | 2 | 2018 | 285 | 0.180 |
Why?
|
| Single-Blind Method | 1 | 2019 | 156 | 0.170 |
Why?
|
| Artificial Intelligence | 1 | 2021 | 261 | 0.170 |
Why?
|
| Tachycardia | 1 | 2018 | 34 | 0.170 |
Why?
|
| Computer Security | 1 | 2018 | 16 | 0.170 |
Why?
|
| Inferior Wall Myocardial Infarction | 1 | 2018 | 2 | 0.170 |
Why?
|
| Myocardial Contraction | 1 | 2019 | 243 | 0.160 |
Why?
|
| Intensive Care Units | 1 | 2021 | 361 | 0.160 |
Why?
|
| Recurrence | 5 | 2018 | 1128 | 0.160 |
Why?
|
| Thromboembolism | 1 | 2018 | 117 | 0.150 |
Why?
|
| Forecasting | 2 | 2015 | 305 | 0.150 |
Why?
|
| Cardiology | 1 | 2017 | 120 | 0.150 |
Why?
|
| United States | 5 | 2022 | 6474 | 0.150 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 716 | 0.140 |
Why?
|
| Glomerular Filtration Barrier | 1 | 2015 | 1 | 0.140 |
Why?
|
| Coronary Angiography | 2 | 2014 | 218 | 0.130 |
Why?
|
| Medicare | 1 | 2017 | 378 | 0.130 |
Why?
|
| Hypertrophy, Right Ventricular | 1 | 2014 | 32 | 0.130 |
Why?
|
| Disease-Free Survival | 5 | 2017 | 1204 | 0.120 |
Why?
|
| Quality Improvement | 1 | 2017 | 411 | 0.120 |
Why?
|
| Societies, Medical | 1 | 2017 | 571 | 0.120 |
Why?
|
| Heart Valve Diseases | 1 | 2014 | 102 | 0.120 |
Why?
|
| Walking | 1 | 2014 | 84 | 0.120 |
Why?
|
| Animals | 4 | 2022 | 26197 | 0.110 |
Why?
|
| Pharyngitis | 1 | 2012 | 16 | 0.110 |
Why?
|
| Streptococcus pyogenes | 1 | 2012 | 34 | 0.110 |
Why?
|
| Creatine Kinase | 1 | 2012 | 49 | 0.110 |
Why?
|
| Heart Failure, Systolic | 1 | 2012 | 7 | 0.110 |
Why?
|
| Chest Pain | 1 | 2012 | 37 | 0.110 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2014 | 166 | 0.110 |
Why?
|
| Troponin T | 1 | 2012 | 35 | 0.110 |
Why?
|
| Time Factors | 2 | 2019 | 5181 | 0.110 |
Why?
|
| Stem Cell Transplantation | 1 | 2013 | 183 | 0.110 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2017 | 1200 | 0.100 |
Why?
|
| Smad3 Protein | 1 | 2011 | 15 | 0.100 |
Why?
|
| Tachycardia, Paroxysmal | 1 | 2011 | 2 | 0.100 |
Why?
|
| Equipment Design | 1 | 2012 | 404 | 0.100 |
Why?
|
| Motor Activity | 1 | 2014 | 325 | 0.100 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2011 | 40 | 0.100 |
Why?
|
| RNA, Neoplasm | 1 | 2011 | 87 | 0.100 |
Why?
|
| Adult | 7 | 2021 | 25287 | 0.100 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2015 | 337 | 0.100 |
Why?
|
| Hypertension, Pulmonary | 1 | 2014 | 332 | 0.100 |
Why?
|
| Renal Dialysis | 1 | 2013 | 340 | 0.100 |
Why?
|
| Green Fluorescent Proteins | 1 | 2011 | 302 | 0.100 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2011 | 98 | 0.090 |
Why?
|
| Patient Care Team | 1 | 2012 | 273 | 0.090 |
Why?
|
| Myocardial Infarction | 1 | 2012 | 358 | 0.090 |
Why?
|
| Biomarkers | 2 | 2012 | 1671 | 0.090 |
Why?
|
| Signal Transduction | 2 | 2011 | 3198 | 0.090 |
Why?
|
| Young Adult | 3 | 2021 | 5883 | 0.090 |
Why?
|
| Axin Protein | 1 | 2008 | 4 | 0.090 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2008 | 37 | 0.090 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2008 | 48 | 0.080 |
Why?
|
| Kidney Failure, Chronic | 1 | 2013 | 492 | 0.080 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2008 | 61 | 0.080 |
Why?
|
| Diagnosis, Differential | 1 | 2012 | 1536 | 0.080 |
Why?
|
| Cytosol | 1 | 2008 | 189 | 0.080 |
Why?
|
| Age Factors | 1 | 2012 | 1827 | 0.080 |
Why?
|
| Mice, Transgenic | 1 | 2011 | 1519 | 0.080 |
Why?
|
| Behavior | 1 | 2007 | 89 | 0.080 |
Why?
|
| Base Sequence | 1 | 2011 | 2321 | 0.080 |
Why?
|
| Reproducibility of Results | 3 | 2019 | 2667 | 0.070 |
Why?
|
| Interprofessional Relations | 1 | 2007 | 121 | 0.070 |
Why?
|
| Perception | 1 | 2007 | 160 | 0.070 |
Why?
|
| Mice, Knockout | 1 | 2011 | 1894 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2014 | 856 | 0.070 |
Why?
|
| Clinical Clerkship | 1 | 2007 | 116 | 0.070 |
Why?
|
| Mice | 2 | 2011 | 11056 | 0.070 |
Why?
|
| Zebrafish | 1 | 2008 | 304 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2011 | 1196 | 0.070 |
Why?
|
| Repressor Proteins | 1 | 2008 | 397 | 0.070 |
Why?
|
| RNA, Messenger | 1 | 2011 | 1966 | 0.070 |
Why?
|
| Comorbidity | 2 | 2021 | 934 | 0.070 |
Why?
|
| Ethics, Medical | 1 | 2007 | 304 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 1 | 2011 | 3050 | 0.060 |
Why?
|
| Prevalence | 2 | 2018 | 1222 | 0.060 |
Why?
|
| Sensitivity and Specificity | 2 | 2021 | 1971 | 0.060 |
Why?
|
| Models, Biological | 1 | 2011 | 1732 | 0.060 |
Why?
|
| Atropine | 1 | 2023 | 59 | 0.060 |
Why?
|
| Heart Block | 1 | 2023 | 32 | 0.060 |
Why?
|
| Cell Line | 1 | 2008 | 2452 | 0.060 |
Why?
|
| Cardiac Conduction System Disease | 1 | 2023 | 6 | 0.060 |
Why?
|
| Constriction, Pathologic | 1 | 2004 | 206 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2021 | 1787 | 0.060 |
Why?
|
| Surveys and Questionnaires | 3 | 2021 | 2433 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2012 | 1343 | 0.060 |
Why?
|
| Students, Medical | 1 | 2007 | 383 | 0.060 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2023 | 164 | 0.060 |
Why?
|
| Confidence Intervals | 2 | 2012 | 229 | 0.050 |
Why?
|
| Endocardium | 1 | 2020 | 76 | 0.050 |
Why?
|
| Mortality | 1 | 2021 | 148 | 0.050 |
Why?
|
| Survival Rate | 2 | 2015 | 1852 | 0.050 |
Why?
|
| Vascular System Injuries | 1 | 2020 | 29 | 0.050 |
Why?
|
| Chi-Square Distribution | 2 | 2014 | 358 | 0.050 |
Why?
|
| Hemodynamics | 1 | 2023 | 701 | 0.050 |
Why?
|
| Prosthesis Design | 1 | 2020 | 272 | 0.040 |
Why?
|
| Disease Progression | 2 | 2014 | 1504 | 0.040 |
Why?
|
| Pericardium | 1 | 2019 | 63 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2012 | 1535 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2021 | 1651 | 0.040 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2017 | 42 | 0.040 |
Why?
|
| Congresses as Topic | 1 | 2017 | 116 | 0.040 |
Why?
|
| Heart | 1 | 2020 | 528 | 0.040 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2020 | 570 | 0.040 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2017 | 203 | 0.030 |
Why?
|
| Boston | 1 | 2015 | 32 | 0.030 |
Why?
|
| Cardio-Renal Syndrome | 1 | 2015 | 6 | 0.030 |
Why?
|
| Contrast Media | 1 | 2020 | 1061 | 0.030 |
Why?
|
| Endpoint Determination | 1 | 2014 | 60 | 0.030 |
Why?
|
| Tissue Survival | 1 | 2014 | 13 | 0.030 |
Why?
|
| Capillaries | 1 | 2014 | 91 | 0.030 |
Why?
|
| Massachusetts | 1 | 2013 | 33 | 0.030 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2014 | 47 | 0.030 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2014 | 90 | 0.030 |
Why?
|
| Cardiac Output | 1 | 2012 | 152 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 986 | 0.030 |
Why?
|
| Child | 1 | 2023 | 6776 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 306 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 855 | 0.030 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2011 | 24 | 0.030 |
Why?
|
| Adolescent | 1 | 2004 | 8849 | 0.030 |
Why?
|
| Echocardiography, Doppler | 1 | 2012 | 185 | 0.030 |
Why?
|
| Risk | 1 | 2012 | 671 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2012 | 822 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2013 | 954 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 994 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2013 | 831 | 0.020 |
Why?
|
| Heart Transplantation | 1 | 2014 | 694 | 0.020 |
Why?
|
| Observation | 1 | 2007 | 37 | 0.020 |
Why?
|
| Italy | 1 | 2007 | 104 | 0.020 |
Why?
|
| Japan | 1 | 2007 | 307 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 1161 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2007 | 916 | 0.020 |
Why?
|
| Reoperation | 1 | 2007 | 585 | 0.020 |
Why?
|
| Quality of Life | 1 | 2012 | 1507 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2007 | 635 | 0.010 |
Why?
|
| Physician-Patient Relations | 1 | 2007 | 606 | 0.010 |
Why?
|